Update on the potential of focused ultrasound applications for Alzheimer’s disease

  • Recherche,

le 27 novembre 2017

Conférencière invitée (avec le soutien de la SFR):
Dr Isabelle Aubert, PhD, Université de Toronto, Institut de recherche Sunnybrook, Canada

Date et lieu :
Lundi 27 novembre à 10h, salle des séminaires de l’UMR930, CHU Bretonneau, Tours.

Transcranial MRI-guided focused ultrasound (MRIgFUS) has entered the clinic for thermal and non-thermal applications in cases of neurological disorders such as essential tremors and Alzheimer’s disease (AD), respectively. Non-thermal MRIgFUS, in conjunction with intravenously injected microbubbles, is used for the delivery of therapeutics from the blood to targeted areas of the brain by increasing the permeability of the blood-brain barrier (BBB) locally and transiently. We previously demonstrated that, in addition to modulating the BBB, MRIgFUS without therapeutic stimulates glial plasticity, reduces plaque load, promotes hippocampal neurogenesis and improved cognitive functions.

The objectives of the current presentation are two-fold. Firstly, provide up-to-date evidence of the impact of MRIgFUS on neuronal and glial plasticity in the brain, without intravenous therapeutics. Secondly, discuss the efficacy of clinically approved antibodies and preclinical therapeutics delivered to the brain using MRIgFUS in a mouse model of AD. Anti-amyloid and pro-regenerative approaches will be addressed (e.g. anti-amyloid beta immunotherapy, growth factor receptors).

The presentation will conclude on challenges and opportunities encountered in the development of MRIgFUS applications from preclinical studies to AD clinical trials.

Contact : emmanuel MOYSE (